Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07139106
PHASE4

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

Sponsor: New York State Psychiatric Institute

View on ClinicalTrials.gov

Summary

This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.

Official title: Dynorphin/Kappa Opioid Receptor Signaling Role in Ketamine's Anti-suicidal Ideation Effect

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-05-01

Completion Date

2028-05-01

Last Updated

2026-03-24

Healthy Volunteers

No

Interventions

DRUG

Ketamine hydrochloride infusion

single racemic ketamine hydrochloride 0.5 mg/kg infusion

Locations (1)

New York State Psychiatric Institute

New York, New York, United States